{"slug":"neuroendocrine","tag":"neuroendocrine","variants":["neuroendocrine"],"description":"No description yet","count":5,"kinds":{"person":5},"related":[{"slug":"trialist","tag":"trialist","shared":3},{"slug":"radioligand","tag":"radioligand","shared":2},{"slug":"canada","tag":"canada","shared":1},{"slug":"mtor","tag":"mtor","shared":1},{"slug":"somatostatin","tag":"somatostatin","shared":1},{"slug":"targeted-therapy","tag":"targeted-therapy","shared":1},{"slug":"uk","tag":"uk","shared":1}],"records":[{"id":"jonathan-strosberg","kind":"person","name":"Jonathan R. Strosberg","route":"/people/jonathan-strosberg/","tldr":"Led NETTER-1, the trial that made lutetium dotatate the first approved radioligand therapy for neuroendocrine tumours."},{"id":"simron-singh","kind":"person","name":"Simron Singh","route":"/people/simron-singh/","tldr":"Led NETTER-2, which moved lutetium dotatate into first-line treatment of higher-grade neuroendocrine tumours."},{"id":"martyn-caplin","kind":"person","name":"Martyn E. Caplin","route":"/people/martyn-caplin/","tldr":"Led CLARINET, which showed lanreotide slows tumour growth and made somatostatin analogues first-line antiproliferative therapy for NETs."},{"id":"james-yao","kind":"person","name":"James C. Yao","route":"/people/james-yao/","tldr":"Led the RADIANT trials that made everolimus a standard therapy for pancreatic and other neuroendocrine tumours."},{"id":"jennifer-chan","kind":"person","name":"Jennifer A. Chan","route":"/people/jennifer-chan/","tldr":"Boston oncologist who led CABINET, the trial that showed cabozantinib delays progression of advanced neuroendocrine tumours after other treatments have failed."}]}